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observation that irritants, which do not induce IL-lO expression, 
are not effective in AA, whereas contact allergens such as DCP are 
[6]. On the other hand, phototherapy may be beneficial in AA. 
Ultraviolet light has been shown to be a potent inducer of IL-lO 
expression in keratinocytes. Theoretically, intralesional application 
of recombinant lL-lO should provide a novel therapeutic approach 
for AA . This approach would be more specific than application of 
a potent contact allergen. 
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A lopecia areata is a common inflammatory disorder affecting the hair and, in some cases, the nails. There is a strong hereditary component with a positive family history ranging from 10% to 25% in different studies, although the true figure may be higher, as 
mild cases are often overlooked. Associations with several major 
histocompatibility complex loci have been reported including 
DR-4 and DQW-7. 
We have been investigating the question "why do some patients 
develop one patch of alopecia areata that regrows without further 
episodes, whereas others develop alopecia totalis or universalis for 
the rest of their lives?" Perhaps the answer lies in genes that 
determine severity rather than susceptibility to alopecia areata. 
One of the major determinants of an inflammatory response in 
the skin is the local production of pro-inflammatory cytokines and 
their antagonists, in particular, interleukin-l (IL-l) and the IL-l 
receptor antagonist (IL-lra). If an individual produces high 
levels of pro-inflammatory cytokines and/or low levels of 
cytokine inhibitor, this would result in the amplification and 
perpetuation of an inflammatory response to any stinlUlus. We 
postulated that polymorphisms within cytokine and related 
genes may be associated with alopecia areata and other inflam­
matory skin diseases. These polymorphisms could result in 
dliferences in cytokine/ cytokine inhibitor production that would 
favor the inflammatory response. 
There are very high levels of interleukin-l a (lL-l a) seques­
tered inside normal keratinocytes that can be released following 
trauma, ultraviolet B irradiation and local infection. We have 
previously demonstrated that there are decreased levels of the 
endogenous antagonist to IL-l, the lL-l receptor antagonist 
(lL-lra) in other inflammatory skin diseases including psoriatic 
plaques. lL-la inhibits human hair-follicle growth and hair-fiber 
production in whole organ cultures [1]. IL-l may therefore play 
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a role in alopecia areata through a direct growth-inhibitory effect 
on hair follicles. The gene for IL-lra (lL-lm) is located on the 
long arm of chromosome 2 on a 430-kb stretch of DNA that also 
contains the genes for IL-la and IL-l {3. 
We have described a variable number tandem repeat poly­
morphism (VNTR) in intron 2 of the IL-l ra gene. Five alleles 
of the system were identified corresponding to two, three, four, 
five, and six copies of an 86 - base pair repeat sequence. We have 
tested the genetic association of alopecia areata with this lL-lra 
polymorphism by comparing the allele frequencies in patients 
with alopecia areata and healthy individuals in a case-control 
association study. 
MATERIALS AND METHODS 
Blood was collected from 261 unrelated , healthy Caucasian individuals from 
the North of England population and from 90 alopecia arcata patients 
attending the dermatology out-patient clinic at the Royal Hallamshire 
Hospital in Sheffield. Prior to genetic analysis, the patients were divided into 
three groups: patchy alopecia , alopecia totalis, and alopecia universalis. 
DNA was extracted using standard methods. 
Polymorphism typing was based on a PCR method as previously de­
scribed [2]. The rate of gene carriage (i.e., the number of individuals 
carrying at least one copy of a specific allele as a proportion of the total 
number of individuals) was calculated. 
RESULTS 
The carriage of allele 2 of the interleukin-l receptor antagonist 
gene is shown in Fig 1. This was 41% in the general population 
compared with 44% in patients with patchy alopecia areata, 66% in 
patients with alopecia totalis, and 77% in alopecia universalis (p 
0.005, OR = 5). 
DISCUSSION 
Alopecia areata seems to be a polygenic disease with genetic 
susceptibility and severity factors. Genetic factors probably interact 
with environmental factors such as infection to trigger the disease. 
The severity of an inflammatory response to an environmental 
trigger may be determined by the balance of pro-inflammatory 
(e.g., IL-la, lL-l(3) and anti-inflammatory cytokines and/or cyto-
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Figure 1. Carriage rate of the allele 2 in the healthy control 
population compared with patients with patchy alopecia areata, 
alopecia totalis, and alopecia universalis. The chi-squared p value 
between the controls and the alopecia totalis group is 0.049 with an odds 
ratio of 2.87 with 95% confidence limits of 1.04 to 8.00. The p value 
between the controls and the alopecia nniversalis group is 0.005 and the 
odds ratio is 5.04 with 95% confidence limits of1.60 to 15.7. Individuals in 
patient groups and the healthy population were unrelated, white Caucasians 
matched for age. 
kine inhibitors (IL-1ra). A ·relative deficiency of the IL-lra could 
result in the perpetuation and increased severity of chronic inflam­
matory skin diseases. 
We have demonstrated that allele 2 of a VNTR polymorphism 
in the interleukin-l receptor antagonist gene is significantly 
increased in patients with alopecia totalis and alopecia univer­
salis. This suggests that allele 2 is not involved in the suscepti­
bility to alopecia areata but affects the severity or extent of the 
disease. 
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We have also demonstrated an association between allele 2 of 
this IL-lra polymorphism and the severity of other inflamma­
tory diseases of epithelial tissues, including systemic lupus 
erythematosus, lichen sclerosis, and inflammatory bowel disease 
[3-5]. 
We have tested several other polymorphisms on chromosome 2 
and have shown that the strongest association with alopecia areata 
is with the IL-1 receptor antagonist gene locus. We are currently 
investigating the VNTR polymorphism in intron 2 of the IL-1ra 
gene to determine if it is associated with a specific production 
phenotype for either the secreted or intracellular form of the 
interleukin-1 receptor antagonist. It is probable that this polymor­
phism is a marker for a functional polymorphism elsewhere in the 
IL-1rn gene or a nearby gene. 
We report an association of an immunoregulatory gene with the 
clinical severity of alopecia areata. Our observation that the same 
allele of this polymorphism is associated with severity in several 
other inflammatory diseases suggests that the IL-1rn gene is a 
general modifying factor in chronic inflammatory diseases of epi­
thelial, and possibly other, tissues. 
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H uman alopecia areata is a relatively common disease characterized by alopecia of acute onset that is focal, diffuse, or combinations of the two. Microscopically, this non-scarring human alope­cia consists of dystrophic anagen or telogen hair 
follicles accompanied by a mononuclear cell infiltrate in and 
around hair follicles [1,2]. Comparable diseases have been 
sporadically reported in Dachshund and Miniature Poodle dogs 
[3,4], Siamese cats [3], Palomino and Appaloosa horses [3], and 
some non-human primate species [3]. A spontaneous mutation 
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occurred in the rat that has been developed as an animal model 
for alopecia areata. The mutant stock has been designated the 
Dungee Experimental Bald Rat [5]. 
A large number of spontaneous and induced mutations with 
alopecia as a major part of their phenotype are described and 
most are available through national repositories, such as the one 
at The Jackson Laboratory. Although initial review of the literature 
and case materials failed to identify a mouse model for alopecia areata, 
in 1991 a single C3H/HeJ female mouse from a large production 
colony was diagnosed with what appeared to be alopecia areata. 
Subsequent investigations have confirmed that alopecia areata occurs 
spontaneously as an aging disease of very low frequency (0.25% of 
female mice, 0.035% of male mice 5-6 months of age) in this strain. 
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